Dermatology is the specialty that learned to treat the skin from the inside.
In February 1979, the New England Journal of Medicine published a report on 14 patients with severe cystic acne. Nothing had worked for them. The report gave them a pill, a form of vitamin A now called isotretinoin, for four months. The acne cleared completely in 13 of the 14. The fourteenth improved by 75%. The clearing lasted: all 14 were still in remission, some 20 months after the pill was stopped. The side effects were on the skin and lips, and they went away when the drug did. A pill had done what no cream could.
Nearly 25 years later, in November 2003, a trial treated psoriasis by blocking a signal in the immune system. TNF is one of the inflammatory signals behind psoriasis. Etanercept blocks it. The trial gave 672 patients etanercept or placebo by injection for 12 weeks. On placebo, 4% of patients saw their psoriasis improve by 75% or more. On the highest dose of etanercept, 49% did. By 24 weeks it was 59%. The skin had cleared because the immune system had been calmed underneath it.
Thirteen years after that, in December 2016, the same idea reached eczema. Two identical trials gave 1,379 adults with moderate-to-severe atopic dermatitis dupilumab or placebo for 16 weeks. Dupilumab blocks two signals, interleukin-4 and interleukin-13, that drive allergic disease. In the first trial, 38% on dupilumab were clear or almost clear, against 10% on placebo. In the second, 36% against 8%. Itch fell, and so did anxiety and depression. The cost was more eye inflammation and injection-site reactions. A disease treated with creams for a century had been treated at its source.
These are three of the thousands of studies that shaped modern dermatology. They taught dermatology that a pill could clear acne for good, that blocking one immune signal could clear psoriasis, and that the same approach could treat eczema, and each time the answer was in a paper years before it was in a textbook.
It is still happening. Recently, in November 2025, the New England Journal of Medicine published a trial of a psoriasis pill. Until now, the drugs that clear psoriasis have been injections. The trial gave 684 adults and adolescents with moderate-to-severe psoriasis icotrokinra, a pill that blocks the interleukin-23 receptor, or placebo. After 16 weeks, 65% on the pill were clear or almost clear, against 8% on placebo. A third had completely clear skin, against 1%. Side effects were as common on the pill as on placebo, 49% in each group, mostly colds. What had needed an injection could now be a pill. Practice follows the literature as it goes. It is a good culture. It has exactly one cost.
The literature grows faster than anyone can read it.
Across the medical topics a dermatologist needs to stay up to date on, from atopic dermatitis and psoriasis to melanoma screening and hair loss, around 140 full-text papers now arrive every week. That is about 600 a month, and more than 7,000 a year. Atopic dermatitis treatment alone is 19 of each week’s 140. Psoriasis biologics are 18. These are not press releases or opinion pieces. They are the same kind of paper as the etanercept trial and the dupilumab trials, and somewhere in each week’s 140 are the handful that will change a prescription.
It is tempting to believe that experience closes the gap, that twenty years of clinic teach what the papers teach. The evidence points the other way. A systematic review of 62 studies found that in most of them, more years in practice went with lower adherence to current standards of care. Experience is not what keeps a dermatologist current. Reading is. And reading is the one thing the week does not have room for.
So we built the tool you need to stay up to date.
We summarise the latest research for you and send it directly to your email inbox, every week, or whenever you choose.
A once-daily pill cleared moderate-to-severe psoriasis in most patients by 16 weeks
TakeawayIn 684 adults and adolescents with moderate-to-severe plaque psoriasis, oral icotrokinra left 65% clear or almost clear at week 16, against 8% on placebo.
Icotrokinra is an oral peptide that binds the interleukin-23 receptor. ICONIC-LEAD, a phase 3 double-blind trial, randomised 684 people aged 12 and over with moderate-to-severe plaque psoriasis, two to one, to icotrokinra 200 mg once daily or placebo.
- •IGA 0/1 at week 16: 65% vs 8% (P < 0.001).
- •PASI 90 at week 16: 50% vs 4% (P < 0.001).
- •Complete clearance: IGA 0 33% vs 1%; PASI 100 27% vs under 1%.